Abbott logo on tablet beside Libre glucose sensor and BinaxNOW test kit in a clinical lab setting. Key Points Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone. Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss. A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case. Interested in ...